Open AccessMetastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland
Author(s) -
Alexander Siebenhüner,
Sara De Dosso,
Alexander Meisel,
Dorothea Wagner,
Markus Borner
Publication year - 2020
Publication title -
oncology research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.553
H-Index - 48
eISSN - 2296-5262
pISSN - 2296-5270
DOI - 10.1159/000506080
Subject(s) - regorafenib , medicine , colorectal cancer , oncology , clinical trial , chemotherapy , refractory (planetary science) , first line treatment , cancer , astrobiology , physics
Metastatic colorectal carcinoma (mCRC) is one of the most prevalent types of cancer worldwide. After tumor progression with first- and second-line treatment, trifluridine (FTD) and tipiracil (TPI) has been shown to be a treatment option.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom